John Wiley and Sons, Inc., and Celera Genomics Announce Linking Agreement
Wiley InterScience to Link with Celera Discovery System
New York, NY and Rockville, MD - November 20, 2001
Patrick Kelly, PhD, Vice President, Scientific Technical and Medical New Business Development at John Wiley & Sons, Inc. (NYSE:JWa)(NYSE:JWb), today announced an agreement with Celera Genomics, (NYSE: CRA), an Applera Corporation business, to develop links between cited article references, abstracts, and full-text articles available on the Wiley InterScience online service and the Celera Discovery System (CDS). This agreement is expected to provide subscribers of both services with more direct access to a broad range of bioinformatics data, full-text articles, and abstracts.
“Thanks to the linking agreement we have with Celera Genomics, researchers in genomics and drug discovery will now be able to move with desktop ease from genetic content in Wiley InterScience to Celera’s CDS and from a gene entry or abstract in CDS back to the appropriate article or abstract in Wiley InterScience,” said Dr. Kelly. “This will provide researchers with a more convenient and comprehensive research tool in the life sciences.”
The content on Wiley InterScience, which includes journals such as Cancer, Proteomics, and Human Mutation, will be linked with the content on CDS, which includes the Human Genome Database, Human Gene Index, Drosophila Genome Database, Drosophila Gene Index, Mouse Genome Reference Database, and SNP Reference Database.
“We are pleased to offer our subscribers access to Wiley’s InterScience database, a premier scientific literature database,” said Jason Mollé, general manager for Celera’s online business. “This is the start of Celera's strategy of directly linking literature to genomic and biological databases. We believe the cross analysis of these key databases should help accelerate breakthrough discoveries.”
CDS is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, and genomic and biological data to advance the discovery process for researchers worldwide. It integrates Celera's exclusive databases, essential public and third-party sources, and analysis and visualization tools in one system.
Wiley InterScience, Wiley's online content service, was launched in the fall of 1997 to respond to the growing worldwide demand for important, reliable, and timely scientific, technical, medical and professional information. Since January 7, 1999, more than 300 journals in full text dating back to January 1997, as well as the full range of services available from Wiley InterScience, are accessible to subscribers and their authorized users. Beginning last year, Wiley InterScience is also the online platform for major reference works, most recently including the Current Protocols Online laboratory manuals series and Patty’s Industrial Hygiene and Toxicology.
About John Wiley & Sons, Inc.
Founded in 1807, John Wiley & Sons, Inc., provides must-have content and services to customers worldwide. Its core businesses include scientific, technical, and medical journals, encyclopedias, books, and online products and services; professional and consumer books and subscription services; and educational materials for undergraduate and graduate students and lifelong learners. Wiley has publishing, marketing, and distribution centers in the United States, Canada, Europe, Asia, and Australia. The company is listed on the New York Stock Exchange under the symbols JWa and JWb. Wiley's recently relaunched Internet site can be accessed at http://www.wiley.com/.
About Applera Corporation and Celera Genomics
Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera is available on the World Wide Web at www.celera.com.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.